Aster Medipharm Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 15-11-2024
- Paid Up Capital ₹ 1.50 M
as on 15-11-2024
- Company Age 15 Year, 8 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.50 M
as on 15-11-2024
- Revenue 20.14%
(FY 2023)
- Profit 254.99%
(FY 2023)
- Ebitda 88.19%
(FY 2023)
- Net Worth 57.46%
(FY 2023)
- Total Assets 6.81%
(FY 2023)
About Aster Medipharm
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹8.50 M.
Jitendra Sharma, Pawan Pareek, and Hemant Pareek serve as directors at the Company.
- CIN/LLPIN
U24232RJ2009PTC030503
- Company No.
030503
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Dec 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Aster Medipharm Private Limited offer?
Aster Medipharm Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, PCD Pharma Franchise.
Who are the key members and board of directors at Aster Medipharm?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jitendra Sharma  | Director | 15-Dec-2009 | Current |
| Pawan Pareek | Director | 15-Dec-2009 | Current |
| Hemant Pareek | Director | 12-Apr-2015 | Current |
Financial Performance of Aster Medipharm.
Aster Medipharm Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 20.14% increase. The company also saw a substantial improvement in profitability, with a 254.99% increase in profit. The company's net worth Soared by an impressive increase of 57.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aster Medipharm?
In 2023, Aster Medipharm had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 May 2023 | ₹5.00 M | Open |
Hdfc Bank Limited Creation Date: 23 Dec 2022 | ₹3.50 M | Open |
How Many Employees Work at Aster Medipharm?
Unlock and access historical data on people associated with Aster Medipharm, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aster Medipharm, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aster Medipharm's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
